Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

A new cream, DHMEQ, reduces allergic skin inflammation effectively.

A man's relapsed leprosy was successfully treated with the antibiotic sparfloxacin.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Secukinumab treatment may cause HBV reactivation and hair discoloration.

Biosimilars lower costs but don't significantly improve access.

A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Upadacitinib may effectively treat resistant lichen planopilaris.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

The FDA approved a new Pfizer drug for hair loss in teens.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Rituximab improved her dermatomyositis better than usual treatments.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.